Johnson & Johnson (BSP:JNJB34)
R$ 60.12 0 (0%) Market Cap: 2.18 Til Enterprise Value: 2.27 Til PE Ratio: 24.52 PB Ratio: 5.08 GF Score: 76/100

Johnson & Johnson at Wells Fargo Healthcare Conference Transcript

Sep 07, 2023 / 02:15PM GMT
Release Date Price: R$52.59
Lawrence H. Biegelsen
Wells Fargo Securities, LLC, Research Division - Senior Medical Device Equity Research Analyst

All right. Good morning. I'm Larry Biegelsen, the medical device analyst at Wells Fargo, and it's my pleasure to host this session with the management team from J&J. With us, we have Ashley McEvoy, Executive Vice President and Worldwide Chairman of Medical Devices, as well as several members from the Abiomed team: Michael Bodner, Global Head of Heart Recovery; Andrew Greenfield, Worldwide President; and Chuck Simonton, Chief Medical Officer and Global VP of Clinical and Medical Affairs.

We're going to start with Abiomed because Ashley is running a few minutes late, but I've been told she will be here momentarily. So gentlemen, thanks so much for being here.

Michael Bodner
Abiomed, Inc. - Global Leader Heart Recovery

Thank you for having us.

Questions & Answers

Lawrence H. Biegelsen
Wells Fargo Securities, LLC, Research Division - Senior Medical Device Equity Research Analyst

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot